5F Itabashi-Honcho Bldg, 36-1 Shimizu-cho, Itabashi-ku Tokyo, 174-0053 Japan[Notice] Mediford Corporation was established on November 1, 2023 by combining the drug development support businesses of LSIM Safety Institute Corporation and LSI Medience Corporation, as a member of PHC Group ( https://www.phchd.com/global ). ******** Mediford Corporation offers services that support a wide range of drug research and development from the exploratory phase to clinical testing, leveraging our testing expertise and experience in advanced analysis, which has been accumulated through our established businesses in clinical trials and non-clinical testing. Our services fall into the following three categories: nonclinical study services, bioanalysis services, and central laboratories services. ・Nonclinical study services: Our services include various safety studies, pharmacodynamic and pharmacokinetic studies for regulatory approval applications as well as exploratory studies in the early stages of research and development at facilities compliant with GLP standards including those for pharmaceuticals, medical devices, regenerative medical products, agricultural chemicals, the Chemical Substances Control Law, etc. We also provide services using PDX (patient-derived xenografts) as well as PDC (patient-derived cells). ・Bioanalysis services: We provide analysis services for drugs, their metabolites, biomarkers, etc. in biological samples. We provide comprehensive support from analytical method development to analytical method validation and measurement of actual samples, from the basic research/exploration stage to the verification/clinical development stage. ・Central laboratory services: We conduct centralized testing for clinical research/ trial/ testing samples from nationwide medical institutions, at LSI Medience, the predecessor of our company. This avoids differences in platforms between institutions, unifies testing methodologies and reference ranges, and facilitates data analysis of testing results. We also leverage our overseas laboratories network to support globalization of drug development, responding to our valuable clients’ demands.

3-30-1, Shimura Itabashi-ku, Tokyo, 174-8555 Japan[Notice] Mediford Corporation was established on November 1, 2023 by combining the drug development support businesses of LSIM Safety Institute Corporation and LSI Medience Corporation, as a member of PHC Group ( https://www.phchd.com/global ). ******** Mediford Corporation offers services that support a wide range of drug research and development from the exploratory phase to clinical testing, leveraging our testing expertise and experience in advanced analysis, which has been accumulated through our established businesses in clinical trials and non-clinical testing. Our services fall into the following three categories: nonclinical study services, bioanalysis services, and central laboratories services. ・Nonclinical study services: Our services include various safety studies, pharmacodynamic and pharmacokinetic studies for regulatory approval applications as well as exploratory studies in the early stages of research and development at facilities compliant with GLP standards including those for pharmaceuticals, medical devices, regenerative medical products, agricultural chemicals, the Chemical Substances Control Law, etc. We also provide services using PDX (patient-derived xenografts) as well as PDC (patient-derived cells). ・Bioanalysis services: We provide analysis services for drugs, their metabolites, biomarkers, etc. in biological samples. We provide comprehensive support from analytical method development to analytical method validation and measurement of actual samples, from the basic research/exploration stage to the verification/clinical development stage. ・Central laboratory services: We conduct centralized testing for clinical research/ trial/ testing samples from nationwide medical institutions, at LSI Medience, the predecessor of our company. This avoids differences in platforms between institutions, unifies testing methodologies and reference ranges, and facilitates data analysis of testing results. We also leverage our overseas laboratories network to support globalization of drug development, responding to our valuable clients’ demands.

14-1, Sunayama, Kamisu-shi, Ibaraki, 314-0255 Japan[Notice] Mediford Corporation was established on November 1, 2023 by combining the drug development support businesses of LSIM Safety Institute Corporation and LSI Medience Corporation, as a member of PHC Group ( https://www.phchd.com/global ). ******** Mediford Corporation offers services that support a wide range of drug research and development from the exploratory phase to clinical testing, leveraging our testing expertise and experience in advanced analysis, which has been accumulated through our established businesses in clinical trials and non-clinical testing. Our services fall into the following three categories: nonclinical study services, bioanalysis services, and central laboratories services. ・Nonclinical study services: Our services include various safety studies, pharmacodynamic and pharmacokinetic studies for regulatory approval applications as well as exploratory studies in the early stages of research and development at facilities compliant with GLP standards including those for pharmaceuticals, medical devices, regenerative medical products, agricultural chemicals, the Chemical Substances Control Law, etc. We also provide services using PDX (patient-derived xenografts) as well as PDC (patient-derived cells). ・Bioanalysis services: We provide analysis services for drugs, their metabolites, biomarkers, etc. in biological samples. We provide comprehensive support from analytical method development to analytical method validation and measurement of actual samples, from the basic research/exploration stage to the verification/clinical development stage. ・Central laboratory services: We conduct centralized testing for clinical research/ trial/ testing samples from nationwide medical institutions, at LSI Medience, the predecessor of our company. This avoids differences in platforms between institutions, unifies testing methodologies and reference ranges, and facilitates data analysis of testing results. We also leverage our overseas laboratories network to support globalization of drug development, responding to our valuable clients’ demands.

1285, Kurisaki-machi Uto-shi, Kumamoto, 869-0425 Japan[Notice] Mediford Corporation was established on November 1, 2023 by combining the drug development support businesses of LSIM Safety Institute Corporation and LSI Medience Corporation, as a member of PHC Group ( https://www.phchd.com/global ). ******** Mediford Corporation offers services that support a wide range of drug research and development from the exploratory phase to clinical testing, leveraging our testing expertise and experience in advanced analysis, which has been accumulated through our established businesses in clinical trials and non-clinical testing. Our services fall into the following three categories: nonclinical study services, bioanalysis services, and central laboratories services. ・Nonclinical study services: Our services include various safety studies, pharmacodynamic and pharmacokinetic studies for regulatory approval applications as well as exploratory studies in the early stages of research and development at facilities compliant with GLP standards including those for pharmaceuticals, medical devices, regenerative medical products, agricultural chemicals, the Chemical Substances Control Law, etc. We also provide services using PDX (patient-derived xenografts) as well as PDC (patient-derived cells). ・Bioanalysis services: We provide analysis services for drugs, their metabolites, biomarkers, etc. in biological samples. We provide comprehensive support from analytical method development to analytical method validation and measurement of actual samples, from the basic research/exploration stage to the verification/clinical development stage. ・Central laboratory services: We conduct centralized testing for clinical research/ trial/ testing samples from nationwide medical institutions, at LSI Medience, the predecessor of our company. This avoids differences in platforms between institutions, unifies testing methodologies and reference ranges, and facilitates data analysis of testing results. We also leverage our overseas laboratories network to support globalization of drug development, responding to our valuable clients’ demands.

1-15-10 Shimura Itabashi-ku Tokyo, 174-0056 Japan[Notice] Mediford Corporation was established on November 1, 2023 by combining the drug development support businesses of LSIM Safety Institute Corporation and LSI Medience Corporation, as a member of PHC Group ( https://www.phchd.com/global ). ******** Mediford Corporation offers services that support a wide range of drug research and development from the exploratory phase to clinical testing, leveraging our testing expertise and experience in advanced analysis, which has been accumulated through our established businesses in clinical trials and non-clinical testing. Our services fall into the following three categories: nonclinical study services, bioanalysis services, and central laboratories services. ・Nonclinical study services: Our services include various safety studies, pharmacodynamic and pharmacokinetic studies for regulatory approval applications as well as exploratory studies in the early stages of research and development at facilities compliant with GLP standards including those for pharmaceuticals, medical devices, regenerative medical products, agricultural chemicals, the Chemical Substances Control Law, etc. We also provide services using PDX (patient-derived xenografts) as well as PDC (patient-derived cells). ・Bioanalysis services: We provide analysis services for drugs, their metabolites, biomarkers, etc. in biological samples. We provide comprehensive support from analytical method development to analytical method validation and measurement of actual samples, from the basic research/exploration stage to the verification/clinical development stage. ・Central laboratory services: We conduct centralized testing for clinical research/ trial/ testing samples from nationwide medical institutions, at LSI Medience, the predecessor of our company. This avoids differences in platforms between institutions, unifies testing methodologies and reference ranges, and facilitates data analysis of testing results. We also leverage our overseas laboratories network to support globalization of drug development, responding to our valuable clients’ demands.